Tesamorelin is approved for one indication, and almost none of its marketing describes that population
Egrifta is approved for excess visceral abdominal fat in HIV-associated lipodystrophy. It is not approved for general fat loss, body recomposition or anti-ageing.
Tesamorelin is a genuine, evidenced, FDA-approved product — approved for one specific indication in one population. Almost none of the online marketing invoking it is describing that population.
Its most significant labelled concern is glucose intolerance and worsening glycaemic control, which is why legitimate prescribing involves glycaemic monitoring. Fluid retention, joint pain and injection-site reactions are also labelled.
It matters beyond its own indication because it is the credible item used to lend weight to a category of analogues — sermorelin, ipamorelin — that share a mechanism and do not share an evidence base. "Approved" is always approved for something, and the useful question is not whether but for what. Full record: tesamorelin.
Filed by the Peptides Editorial research desk. Corrections: the corrections log.